Literature DB >> 2864414

Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs.

S Fujii, T Yokoyama, K Ikegaya, F Sato, N Yokoo.   

Abstract

FK-448 is a potent and specific inhibitor of chymotrypsin, which enhances the intestinal absorption of insulin in rats and dogs resulting in a decrease in blood glucose levels in these animals. In dogs, the immunoreactive insulin (IRI) level of plasma rose proportionally to the decrease in blood glucose level. From in-vitro data, insulin was inactivated by pancreatic enzymes or the supernatants of intestine or liver homogenates. FK-448 suppressed the digestion of insulin by pancreatic enzymes and its enhancement of the intestinal absorption of insulin was found to be related to its inhibition of digestive enzymes, especially chymotrypsin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864414     DOI: 10.1111/j.2042-7158.1985.tb03064.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  15 in total

Review 1.  Transport of peptide and protein drugs across biological membranes.

Authors:  J C Verhoef; H E Boddé; A G de Boer; J A Bouwstra; H E Junginger; F W Merkus; D D Breimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

2.  Degradation of insulin by trypsin and alpha-chymotrypsin.

Authors:  R J Schilling; A K Mitra
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

3.  Absorption enhancement of rectally infused insulin by sodium tauro-24,25-dihydrofusidate (STDHF) in rats.

Authors:  E J van Hoogdalem; C D Heijligers-Feijen; J C Verhoef; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

Review 4.  Oral controlled release technology for peptides: status and future prospects.

Authors:  J A Fix
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Design and in vivo evaluation of an oral delivery system for insulin.

Authors:  M K Marschütz; P Caliceti; A Bernkop-Schnürch
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 6.  Lessons learned from the clinical development of oral peptides.

Authors:  Morten Asser Karsdal; Bente Juul Riis; Nozer Mehta; William Stern; Ehud Arbit; Claus Christiansen; Kim Henriksen
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

7.  Insulin-degrading enzyme in a human colon adenocarcinoma cell line (Caco-2).

Authors:  J P Bai; M J Hsu; W T Shier
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

8.  Stability of acyl derivatives of insulin in the small intestine: relative importance of insulin association characteristics in aqueous solution.

Authors:  H Asada; T Douen; Y Mizokoshi; T Fujita; M Murakami; A Yamamoto; S Muranishi
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

9.  Differential effects of anionic, cationic, nonionic, and physiologic surfactants on the dissociation, alpha-chymotryptic degradation, and enteral absorption of insulin hexamers.

Authors:  Z Shao; Y Li; R Krishnamoorthy; T Chermak; A K Mitra
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

10.  Inhibition of binding of an enzymatically stable thrombin inhibitor to lumenal proteases as an additional mechanism of intestinal absorption enhancement.

Authors:  M Sjöström; L Lindfors; A L Ungell
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.